Role of protein kinase CK2 in antitumor drug resistance

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Biology
• Pharmacology

Background:

• Drug resistance is a primary cause of cancer treatment failure, often linked to altered protein phosphorylation.
• Protein kinase CK2 (Casein Kinase 2) is constitutively active, overexpressed in cancer cells, and promotes survival and proliferation.
• CK2 influences drug resistance mechanisms like drug efflux, DNA repair, and key signaling pathways.

Purpose of the Study:

• To analyze evidence supporting CK2 as a therapeutic target to overcome drug resistance.
• To highlight CK2's role in various drug resistance mechanisms and signaling pathways.
• To discuss the potential of CK2 inhibitors in combination therapies.

Main Methods:

• Review and analysis of existing scientific literature on CK2 and drug resistance.
• Examination of CK2's involvement in signaling pathways (e.g., PI3K/AKT/PTEN, NF-κB, p53).
• Evaluation of the efficacy of CK2 inhibitors in resistant cells and in vivo studies.

Main Results:

• CK2 plays a significant role in multiple drug resistance processes, including drug efflux and DNA repair.
• CK2 modulates critical signaling pathways that enable cancer cells to evade drug treatment.
• Specific CK2 inhibitors demonstrate efficacy in resistant cells, often synergizing with conventional chemotherapeutics.
• CK2 also regulates chaperone systems essential for resistant cell survival.

Conclusions:

• Targeting CK2 is a promising strategy to combat drug resistance in cancer therapy.
• CK2 inhibitors offer a potential approach to resensitize resistant tumors to existing treatments.
• Combination therapies involving CK2 inhibitors warrant further clinical investigation for overcoming pharmacological treatment failure.